TORONTO–VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF), a provider of cannabis products and services and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited and ABcann Medicinals Inc., today announced the launch of Beacon Medical Extra Strength CBD|T Cream, a premium cannabis topical cream for Canadian medical patients.
With 500 mg of cannabidiol (CBD) per 50-gram unit, in a proprietary formulation that includes carefully curated ingredients with anti-oxidant, anti-inflammatory, and analgesic properties, together with skin penetration enhancers, Beacon Medical Extra Strength CBD|T Cream is designed using “entourage” principles to achieve synergies of bioactive ingredients and provide optimal symptom relief for medical conditions.
Beacon Medical Extra Strength CBD|T Cream
Beacon Medical™ Extra Strength CBD|T Cream was developed under the direction of VIVO’s Vice-President, Product Development, Dr. Robert Foldes, in collaboration with experienced dermatology and topical cannabis formulation and manufacturing companies. “I am fortunate to be able to leverage my previous experience with research and development of topical prescription products to treat various skin conditions. We developed this cannabinoid formulation to be amongst the best in the Canadian cannabis marketplace for medical symptom relief, and we look forward to gathering patient outcomes data,” said Dr. Foldes.
“Medical patients use topical cannabis products to provide on-demand relief from a wide variety of symptoms such as localized pain and inflammation. Our team was driven to ensure that Beacon Medical Extra Strength CBD|T Cream offers a high level of potency in a formulation designed to replicate the properties of premium skin creams,” said Carole Chan, Chief Commercial Officer, VIVO. “We’re excited to launch Beacon Medical Extra Strength CBD|T Cream as our first of several planned introductions in the topical cannabis market.” VIVO will follow medical patient outcomes through its Harvest Medicine subsidiary in order to inform its ongoing product development efforts.
The proprietary Beacon Medical Extra Strength CBD|T Cream formula is the only topical cannabinoid formulation to combine CBD extract with the skin bioactive terpenes bisabolol and terpineol, in addition to menthol, peppermint oil and eucalyptus oil. The Beacon Medical™ formulation also uniquely includes coconut and moringa oils, together with other premium ingredients including aloe, beeswax, shea butter, jojoba esters and vitamin E. It is designed to provide fast-acting symptom relief.
The Beacon Medical Extra Strength CBD|T Cream does not contain acrylamides, parabens, parfum, phenoxyethanol, silicon-based polymers, and sodium hydroxide – potential harmful or skin irritating ingredients found in other cannabis topical products on the market. Beacon Medical Extra Strength CBD|T Cream has a mild, minty scent, provides a cooling sensation to the skin, and is packaged in 50 gram jars that preserve freshness.
Beacon Medical™ Extra Strength CBD|T Cream is available to order now through the Canna Farms e-commerce medical marketplace for Canadian medical patients. A second Beacon Medical™ Extra Strength BAL|T Cream will be available in the coming weeks with 250 mg of tetrahydrocannabinol (THC) and 250 mg of CBD per 50-gram unit. VIVO plans to expand its topical offerings later this year under the Lumina brand for health & wellness consumers.
Disclaimer for Forward-Looking Information
Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements regarding: the launch of the Company’s topical CBD cream, the launch of a second topical product in the coming weeks, and the possibility of the launch of other topical products in the future; the cannabinoid formulation may be amongst the best in the Canadian cannabis marketplace for medical symptom relief; the Company will be able to gathering useful patient outcomes data in the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements, including: that the current and future launches will be successful; that patients will find the new products useful for symptom relief; and that the Company may not be able to collect useful patient outcomes data or that such data may not support the efficacy of the new products. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the three months ended March 31, 2021, available on SEDAR, in evaluating the forward‐looking statements contained in this news release, and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
(This information is primarily sourced from Vivo. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).